Autobio Diagnostics Co Ltd

Autobio Diagnostics held its 2026 first-half results briefing on September 30, attended by four senior executives including Chairman Miao Yongjun and Vice President and Board Secretary Fang Ruikuan. In the first half of 2026, the company achieved total operating revenue of 2.058 billion yuan, down 0.12 percent year on year; net profit attributable to shareholders of 497 million yuan, down 12.94 percent; non-GAAP net profit of 493 million yuan, down 9.73 percent; and net cash flow from operating activities of 216 million yuan, down 47.38 percent. In response to an investor question about whether the overseas revenue target of 600 million yuan set at the beginning of the year can be met, the company said it has not adjusted the overseas sales target for now, and that meeting it faces considerable pressure. In the first half, overseas business revenue was 220 million yuan, up 40.13 percent year on year. For full-year 2025, overseas business revenue was 384 million yuan, up 34.96 percent, with products covering more than 120 countries and regions worldwide. The company said that as the share of sales from its own products increases, gross margin should rise. It also said the assembly line business, namely biochemistry and immunoassay, remains the most important growth driver at present, while microbiology and quality control products are growing rapidly with relatively large scale and are gradually contributing more to profit. It will take some time for tandem mass spectrometry, sequencing, and molecular businesses to make a contribution.

Autobio Diagnostics has released its 2026 interim report, showing net profit attributable to the parent company of 497 million yuan, a decrease of 12.94% compared with the same period last year. Total operating revenue was 2.058 billion yuan, a slight decline of 0.12% year on year. Net cash inflow from operating activities was 216 million yuan, down 47.38% year on year. The latest asset-liability ratio was 25.60%, gross margin was 67.25%, and diluted earnings per share was 0.87 yuan.

Autobio Diagnostics released its 2026 half-year report. Net profit attributable to the parent in the first half was 497 million yuan, down 12.9% year on year. Operating revenue was 2.06 billion yuan, down 0.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 493 million yuan, down 9.7% year on year. Net operating cash flow was 216 million yuan, down 47.4% year on year. In the second quarter, operating revenue was 1.07 billion yuan, up 0.1% year on year, and net profit attributable to the parent was 261 million yuan, down 13.4% year on year. Research and development expenses in the first half reached 302 million yuan, accounting for 14.68% of operating revenue. The company's products have entered more than 120 countries and regions in overseas markets.